On Wednesday of JP Morgan week last month, pharmaphorum editor-in-chief Jonah Comstock sat down at the Zeppelin Hotel with Claudia Ulbrich, CEO of Germany-based Cardior, to learn a little more abou
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing ne
German injectable medicines specialist Fresenius Kabi has made a pair of deals to kickstart its new strategic direction, including a majority stake in mAbxience that bolsters its position i
The Highly Potent Active Pharmaceutical Ingredients conference will be hosting 2 interactive half day post-conference workshops on the 23rd May, presented by HPAPI Project Services Limited
As the demand for information outside of approved labeling continues to rise, the FDA has been called by the industry to provide guidance that governs off-label communications.
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas